Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aspreva, Roche cancel CellCept filing

Aspreva (TSX:ASV; ASPV) and partner Roche (SWX:ROG) said they have decided not to proceed with a

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE